Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASN-002 Alone or with 5-FU in Nodular Basal Cell Carcinoma
NCT02550678Phase 2Completed
- Sponsor
- Ascend Biopharmaceuticals Ltd.
- Start
- Sep 2015
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of gusacitinib in basal cell carcinoma (nodular) (BCC) (5 arms), sponsored by Ascend Biopharmaceuticals Ltd. Primary endpoint: Incidences of ASN-002 related Adverse Event at 6 months. Started Sep 2015; status: completed.
02
Drugs
gusacitinib
03
Conditions
basal cell carcinoma (nodular) (BCC)
Beyond the preview
Go deeper on NCT02550678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02550678.